The Fast Track
_____________________________________________________________
Dermisonics Develops Working Model of Antiseptic Wand In The $1.2 Billion Wound Care Market
Now In Talks With U.S. Army to Build Battlefield Version _____________________________________________________________
The C0mpany: Dermisonics Inc. Sect or: Conglomerates Symb 01: DMSI {lt2} $0.47
We have reviewed this new stock in our listings and we are more than excited. This company has developed a new antiseptic delvery system that not only makes the application of antiseptic to wounds, its ability to penitrate deeper than surface cover can actually help prevent against needed amputations due to uncontrolled infections.
It is no wonder the US Military is interested in bulding a battlefield version to help protect our soldiers by better equiping the field medics.
Just check out their website and reveiw the full news release below. With an annoucement like this in the market we are very excited to see where this stock goes tomorrow.
The Headlin es:
WEST CONSHOHOCKEN, Pa., Feb. 6 /CNW/ -- Dermisonics, Inc. (OTC Bulletin Board: DMSI.OB), a pioneer in the development of ultrasonic transdermal drug-delivery technologies, announced today that it has completed the first working model of its A-Wand antiseptic delivery system and is in talks with the Army Institute of Surgical Research under the Combat Casualty Care Research Program to develop a battlefield version.
The A-Wand (TM) is a handheld, portable, ultrasonic wand device for applying antiseptic solutions to cuts, abrasions and wounds with a replaceable Patch-Cap (TM), which holds up to 40 ml of antiseptic solution. It uses alternating ultrasonic waveforms to enlarge the diameter of the skin pores enabling antiseptics to permeate through the skin (Stratum Corneum) into the dermis through the sweat pores.
Attacks Critical Problem of Infections in Wounded Soldiers -- Infection is a major, potentially lethal, battlefield hazard for wounded soldiers before they can receive full medical treatment in a hospital. The Medic on the scene applies antiseptic and bandages the wound but the antiseptic only affects the outermost layers of the damaged tissue. Infection frequently results and is a major cause of amputations.
The A-Wand Encapsulates the Wounded Area with Antiseptic -- The A-Wand would be used by Medics in the field, by Mash units and for follow-up wound care to significantly reduce this hazard. Through the use of the A-Wand's ultrasound system, the antiseptic solution is "pushed" to the deeper tissue where it can more effectively fight infection by surrounding and encapsulating the wounded area with antiseptic. It also has the added advantage of being able to penetrate scared tissue without damaging this basic body defense system.
Technology inventor and Dermisonics Executive Vice-President Bruce Redding commented, "The A-Wand represents a huge opportunity for Dermisonics and the various patients who could benefit from increased infection-resistant technologies. Dermisonics especially is pleased by the response from the US Army and we hope this technology finds acceptance in the field as soon as possible"
The Next Generation in the $1.2 Billion Wound Care Market -- The Company believes the A-Wand will represent a significant shift in wound-care medical science and will fundamentally change the $1.2 billion wound-care market.
Industry Opportunity and Receptivity -- As a harbinger of its immediate industry impact, the Company has already received, in addition to the military, strong indications of interest from major companies in the pharmaceutical and hospital fields.
{ov1}
Dermisonics is an intellectual property company and advanced technology incubator that is primarily focused on the ongoing development, testing and eventual commercialization of a transdermal patch that has been designed to facilitate the efficient and needle-free delivery of drugs with large molecular structures into the bloodstream. Its breakthrough system, called the U-Strip, is based on a radical integration of microelectronics and ultrasonic science with a product-carrying patch, and represents a quantum leap in non- invasive, transdermal delivery technology. Tests have shown that this system facilitates the transdermal delivery of insulin as well as potentially at least 175 other existing drugs that at present cannot be effectively delivered through the pores of the skin using conventionally available transdermal technology due to their large molecular size. The Company has also developed other portable ultrasonic systems for applications in the medical (Antiseptic Wand) and skin care (U-Wand) fields.
G00D TRAD1NG
______________
Information within this em ail contains 4rward l0 0king statements within the meaning of Section 27A of the Secu rities Act of nineteen thirty three and Section 21B of the Securi ties Exch ange Act of nineteen thirty four. Any statements that express or involve discussions with respect to predi ctions, expec tations, beli efs, pla ns, projec tions, objec tives, goa ls, ass umptions or future events or performance are not statements of historical fact and may be 4rward 1o0king statements. Don't rely on them to make a decision. As with many micr ocap st0c ks, today's com pany has disclosable material items you need to consider in order to make an informed and intelligent in_vest ment decision. These items include: a reliance on loans from offi cers, some related party transactions, a goin concern opinion from its auditor, no reven ues in its most recent quar ter, a large accumulated deficit, default on not es pay able that could cause the com pany to lose its intellectual property, and potential litigation over its technology. It is not an operating comp any and is going to need fin ancing. Read the Company's S E C Fili ngs now, right now, before you inve st. None of the material within this report shall be construed as any kind of in vestment advi ce or solicitat ion. Many of these small compa nies are on the verge of bankr uptcy. You can lose all your m0ny by in-ves ting in this st0c k. In compliance with the Securi ties Act of 19 33, Sec tion 17(b),we disclose the receipt of four hundred twenty five thousand free trading shares received from a third party, not an officer, director or affiliate shareholder for our services. We intend to sell our stock now. This could cause the stock to go down, resulting in losses for you. All factual informa tion in this report was gathered from public sources, including but not limited to Comp any Pre ss Releas es and Fili ngs.